Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2022 Mar 17

PMID 35298000

Authors

E John Tokarsky

Jesse C Crow

Lillian M Guenther

John Sherman

Cenny Taslim

Gabriela Alexe

Kathleen I Pishas

Galen Rask

Blake S Justis

Ana Kasumova

Kimberly Stegmaier

Stephen L Lessnick

Emily R Theisen

Affiliations

Soon will be listed here.

Abstract

Implications: These findings demonstrate that mitochondrial dysfunction modulates SP-2509 efficacy and suggest that new therapeutic strategies combining LSD1 with agents that prevent mitochondrial dysfunction may benefit patients with this aggressive malignancy.

Citing Articles

Unlocking epigenetics for precision treatment of Ewing's sarcoma.

Fan Z, Dong S, Wang N, Khawar M, Wang J, Sun H Chin J Cancer Res. 2024; 36(3):322-340.

PMID: 38988487 PMC: 11230886. DOI: 10.21147/j.issn.1000-9604.2024.03.08.

Inhibition of LSD1 via SP2509 attenuated the progression of rheumatoid arthritis.

Yu Z, Li P, Gao D, Hu Y, Xia F, Liu L Immunol Res. 2024; 72(4):797-810.

PMID: 38722530 DOI: 10.1007/s12026-024-09486-5.

Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma.

Dreher R, Theisen E Front Oncol. 2023; 12:1076581.

PMID: 36686841 PMC: 9846348. DOI: 10.3389/fonc.2022.1076581.

Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities.

Li M, Chen C Biomedicines. 2022; 10(6).

PMID: 35740349 PMC: 9219675. DOI: 10.3390/biomedicines10061325.

References

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Tsafou K, Katschnig A, Radic-Sarikas B, Mutz C, Iljin K, Schwentner R . Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers. Oncotarget. 2018; 9(57):31018-31031. PMC: 6089552. DOI: 10.18632/oncotarget.25760. View

Wei G, Badis G, Berger M, Kivioja T, Palin K, Enge M . Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 2010; 29(13):2147-60. PMC: 2905244. DOI: 10.1038/emboj.2010.106. View

Yang D, Kim J . Mitochondrial Retrograde Signalling and Metabolic Alterations in the Tumour Microenvironment. Cells. 2019; 8(3). PMC: 6468901. DOI: 10.3390/cells8030275. View

Sankar S, Theisen E, Bearss J, Mulvihill T, Hoffman L, Sorna V . Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res. 2014; 20(17):4584-97. PMC: 4155010. DOI: 10.1158/1078-0432.CCR-14-0072. View

Pishas K, Lessnick S . Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation. Oncotarget. 2018; 9(92):36413-36429. PMC: 6284858. DOI: 10.18632/oncotarget.26326. View

Burningham Z, Hashibe M, Spector L, Schiffman J . The epidemiology of sarcoma. Clin Sarcoma Res. 2012; 2(1):14. PMC: 3564705. DOI: 10.1186/2045-3329-2-14. View

Marchetto A, Ohmura S, Orth M, Knott M, Colombo M, Arrigoni C . Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma. Nat Commun. 2020; 11(1):2423. PMC: 7228971. DOI: 10.1038/s41467-020-16244-2. View

Liu Z, Butow R . Mitochondrial retrograde signaling. Annu Rev Genet. 2006; 40:159-85. DOI: 10.1146/annurev.genet.40.110405.090613. View

10.

Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C . Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet. 1988; 32(2):229-38. DOI: 10.1016/0165-4608(88)90285-3. View

11.

Shalem O, Sanjana N, Hartenian E, Shi X, Scott D, Mikkelson T . Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2013; 343(6166):84-87. PMC: 4089965. DOI: 10.1126/science.1247005. View

12.

Groenendijk F, Bernards R . Drug resistance to targeted therapies: déjà vu all over again. Mol Oncol. 2014; 8(6):1067-83. PMC: 5528618. DOI: 10.1016/j.molonc.2014.05.004. View

13.

Correia-Melo C, Ichim G, Tait S, Passos J . Depletion of mitochondria in mammalian cells through enforced mitophagy. Nat Protoc. 2016; 12(1):183-194. DOI: 10.1038/nprot.2016.159. View

14.

Shi Y, Lan F, Matson C, Mulligan P, Whetstine J, Cole P . Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004; 119(7):941-53. DOI: 10.1016/j.cell.2004.12.012. View

15.

Doench J, Fusi N, Sullender M, Hegde M, Vaimberg E, Donovan K . Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016; 34(2):184-191. PMC: 4744125. DOI: 10.1038/nbt.3437. View

16.

Riggi N, Knoechel B, Gillespie S, Rheinbay E, Boulay G, Suva M . EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014; 26(5):668-681. PMC: 4492343. DOI: 10.1016/j.ccell.2014.10.004. View

17.

Martinez-Reyes I, Chandel N . Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020; 11(1):102. PMC: 6941980. DOI: 10.1038/s41467-019-13668-3. View

18.

Boulay G, Sandoval G, Riggi N, Iyer S, Buisson R, Naigles B . Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain. Cell. 2017; 171(1):163-178.e19. PMC: 6791823. DOI: 10.1016/j.cell.2017.07.036. View

19.

Theisen E, Pishas K, Saund R, Lessnick S . Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget. 2016; 7(14):17616-30. PMC: 4951237. DOI: 10.18632/oncotarget.7124. View

20.

Bennani-Baiti I, Machado I, Llombart-Bosch A, Kovar H . Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 2012; 43(8):1300-7. DOI: 10.1016/j.humpath.2011.10.010. View